drugset / Trial / NCT02852876

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

NCT02852876

Phase 1 Completed 72 enrolled Astellas Pharma Europe Ltd.
RandomizedCrossoverDouble-blindBasic science

Summary

The objective of this study is to evaluate the safety and tolerability of single rising doses of ASP2151 under fasted condition in healthy male subjects. The study will also evaluate the pharmacokinetics (PK) of a single dose of ASP2151 under fasted versus fed conditions in healthy male subjects.

Timeline

Start
2005-09
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amenamevir Small molecule Oral